UT Southwestern Medical Centre
Welcome,         Profile    Billing    Logout  
 25 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iyengar, Puneeth
GRECO-1, NCT04476797: Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

Terminated
1/2
47
US
GC4711 +SBRT, rucosopasem manganese, Placebo +SBRT
Galera Therapeutics, Inc.
SBRT, NSCLC, Non-metastatic
11/23
11/23
NCT04906746: Ruxolitinib for Cancer Cachexia

Recruiting
1
10
US
Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Tu Dan, Incyte Corporation
Stage IV Non-small Cell Lung Cancer, Cachexia
02/25
02/25
Kilmer, Suzanne
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
Sher, David
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting
2
102
Canada, US
Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT
RTOG Foundation, Inc., Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/27
07/29
Oz, Orhan
RAPID-WATER, NCT05134012 / 2021-006295-17: RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (-FLOW)

Recruiting
3
215
Europe, Canada, US
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
MedTrace Pharma A/S, MedTrace Pharma A/S
Coronary Artery Disease
12/24
06/25
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hourglass May 2024 - Dec 2024 : Completion of enrollment in P2 portion for mCRPC
Recruiting
2/3
60
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
07/26
01/31
Neufeld, Sarah
POTEN-C, NCT03525262: Prostate Oncologic Therapy While Ensuring Neurovascular Conservation

Active, not recruiting
2
124
US
30Gy (Gray) planning target volume (PTV)
University of Texas Southwestern Medical Center, Boston Scientific Corporation
Prostate Cancer Adenocarcinoma
05/27
05/27
KEVLARx, NCT05966194: RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Recruiting
2
216
US
RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
EpicentRx, Inc.
Oral Mucositis
07/25
10/25
NCT05021237: Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer

Recruiting
2
30
US
Ultra-fractionated radiation therapy
University of Texas Southwestern Medical Center, Elekta Limited
Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix, Cervical Cancer, Metastasis
08/28
08/28
NCT06044857: PSMA PET Response Guided SabR in High Risk Pca

Recruiting
1
20
US
68-Ga PSMA11, Illucix, Telix
University of Texas Southwestern Medical Center, Once Upon a Time Foundation, Telix International Pty Ltd
Prostate Adenocarcinoma
11/26
11/26
ARTIA-Cervix, NCT05197881: Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

Recruiting
N/A
125
US
Varian Ethos Adaptive Radiation Therapy
Varian, a Siemens Healthineers Company
Cervical Cancer by FIGO Stage 2018
05/26
05/28
NCT06353321: Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

Recruiting
N/A
25
US
PET-CT imaging subsystem of the RefleXion X1 System Device
University of Texas Southwestern Medical Center, RefleXion Medical
Prostate Cancer
12/25
12/25
Gilmore, Linda A
No trials found

Download Options